cellect.co valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Home |
| Description | Enabling Cell Home About Science Solutions Partners Investors News Enabling Cell Therapy Our ApoGraft™ technology turns production of cell-based therapies into a simple |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 75.2.70.75 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
cellect.co Valuation
|
US$6,814,120
Last updated: 2022-06-25 16:15:52
cellect.co has Semrush global rank of 1,553,290. cellect.co has an estimated worth of US$ 6,814,120, based on its estimated Ads revenue. cellect.co receives approximately 786,245 unique visitors each day. Its web server is located in United States, with IP address 75.2.70.75. According to SiteAdvisor, cellect.co is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$6,814,120 |
| Daily Ads Revenue | US$6,290 |
| Monthly Ads Revenue | US$188,699 |
| Yearly Ads Revenue | US$2,264,385 |
| Daily Unique Visitors | 52,417 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| cellect.co. | A | 3599 | IP: 75.2.70.75 |
| cellect.co. | A | 3599 | IP: 99.83.190.102 |
| cellect.co. | NS | 3600 | NS Record: ns72.domaincontrol.com. |
| cellect.co. | NS | 3600 | NS Record: ns71.domaincontrol.com. |
| cellect.co. | MX | 3600 | MX Record: 5 alt2.aspmx.l.google.com. |
| cellect.co. | MX | 3600 | MX Record: 1 aspmx.l.google.com. |
| cellect.co. | MX | 3600 | MX Record: 10 aspmx2.googlemail.com. |
| cellect.co. | MX | 3600 | MX Record: 10 aspmx3.googlemail.com. |
| cellect.co. | MX | 3600 | MX Record: 5 alt1.aspmx.l.google.com. |
| cellect.co. | TXT | 3600 | TXT Record: google-site-verification=wgzEa6n3YpwLxPG-Ngplcq0TStwN9ICqvC_1FozIQks |
| cellect.co. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com include:_spf.google.com -all |
| cellect.co. | TXT | 3600 | TXT Record: google-site-verification=vSloaD7FqGONAo_GZZ876da-pCB5gu2Hw2X0fmsmzaQ |
HtmlToTextCheckTime:2022-06-25 16:15:52
| Home About Science Solutions Partners Investors News Enabling Cell Therapy Our ApoGraft™ technology turns production of cell-based therapies into a simple, safe and inexpensive process Learn more about Cellect Understanding Cellect in 2 minutes Key Milestones JUL 2016 Cellect raises $8.4M JAN 2017 US Patent Notice of Allowance FEB 2017 First Cancer Patient Treated In Phase I/II Trial Positive Clinical Results MAR 2017 Successful First Cancer Patient Stem Cell Transplant JUN 2017 Cellect Receives Russian Patent SEP 2017 FDA Grants Cellect Orphan Drug Status for ApoGraft™ SEP 2017 Cellect raises $4.3M JAN 2018 Positive Clinical Trial Results100% Acceptance and Zero Related Adverse Events JAN 2018 Cellect raises $4.0M JAN 2018 Opening 2nd Clinical Trial Site DSMB Approves Dose Escalation APR 2018 Successfully completes POC testing for scalable production of ApoTainer™ JUL 2018 Signs Collaboration Agreement with Dresden University AUG 2018 Cellect Granted Key European |
HTTP Headers
HTTP/1.1 301 Moved Permanently Server: openresty Date: Mon, 25 Oct 2021 05:28:08 GMT Content-Type: text/html Content-Length: 166 Connection: keep-alive Location: https://cellect.co/ HTTP/2 301 server: openresty date: Mon, 25 Oct 2021 05:28:08 GMT content-type: text/html content-length: 166 location: https://www.cellect.co/ HTTP/2 200 server: openresty date: Mon, 25 Oct 2021 05:28:09 GMT content-type: text/html content-length: 20633 content-security-policy: frame-ancestors 'self' x-frame-options: SAMEORIGIN x-lambda-id: 0554d0ff-7ab5-4abb-9a1d-0e4f1a1c584d accept-ranges: bytes via: 1.1 varnish age: 20341 x-served-by: cache-dca17729-DCA x-cache: HIT x-cache-hits: 1 x-timer: S1635139689.091943,VS0,VE1 vary: Accept-Encoding x-cluster-name: us-east-1-prod-edge-eks-15 |